USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Aug 2, 2022 | Jun 2022 | $-0.57 | $-0.66 | $-0.67 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Aug 2, 2022 | Jun 2022 | $32.62M | $29.84M | $27.18M |
Aerie Pharmaceuticals's next earnings date is Tuesday, Aug 2, 2022 for the fiscal quarter ending Jun 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Jun 2022 | 10 | $-0.57 | $-0.72 | $-0.44 |
Sep 2022 | 10 | $-0.52 | $-0.70 | $-0.42 |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 8 | $-2.13 | $-2.74 | $-1.61 |
Dec 2023 | 8 | $-1.28 | $-1.81 | $-0.54 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Jun 2022 | 4 / 3 | $-0.62 | $-0.62 | $-0.66 |
Sep 2022 | 5 / 2 | $-0.60 | $-0.60 | $-0.61 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 7 / 1 | $-2.34 | $-2.34 | $-2.20 |
Dec 2023 | 5 / 2 | $-1.37 | $-1.37 | $-1.21 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|---|---|---|---|
Jun 2022 | 9 | $32.62M | $30.50M | $33.80M |
Sep 2022 | 9 | $35.56M | $33.89M | $37.80M |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 10 | $137.03M | $132.31M | $142.60M |
Dec 2023 | 9 | $180.16M | $155.30M | $200.10M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Aug 2, 2022 | Jun 2022 | $-0.58 | - | - |
May 5, 2022 | Mar 2022 | $-0.65 | $-0.66 | -1.54% |
Feb 24, 2022 | Dec 2021 | $-0.67 | $1.09 | 262.69% |
Nov 4, 2021 | Sep 2021 | $-0.62 | $-0.72 | -16.34% |
Aug 4, 2021 | Jun 2021 | $-0.65 | $-0.67 | -3.08% |
May 5, 2021 | Mar 2021 | $-0.69 | $-0.72 | -4.56% |
Feb 26, 2021 | Dec 2020 | $-0.73 | $-0.80 | -8.49% |
Nov 6, 2020 | Sep 2020 | $-0.80 | $-0.65 | 19.20% |
Aug 7, 2020 | Jun 2020 | $-0.80 | $-0.83 | -3.58% |
May 6, 2020 | Mar 2020 | $-0.78 | $-0.84 | -8.39% |
Feb 20, 2020 | Dec 2019 | $-0.77 | $-0.96 | -24.84% |
Nov 6, 2019 | Sep 2019 | $-0.80 | $-0.86 | -7.66% |
Aug 7, 2019 | Jun 2019 | $-0.88 | $-0.80 | 9.48% |
May 7, 2019 | Mar 2019 | $-0.95 | $-0.78 | 17.51% |
Feb 25, 2019 | Dec 2018 | $-0.87 | $-0.92 | -5.75% |
Nov 6, 2018 | Sep 2018 | $-1.38 | $-1.73 | -25.02% |
Aug 8, 2018 | Jun 2018 | $-0.98 | $-1.14 | -16.07% |
May 8, 2018 | Mar 2018 | $-0.87 | $-0.83 | 4.11% |
Feb 28, 2018 | Dec 2017 | $-1.21 | $-1.38 | -13.84% |
Nov 8, 2017 | Sep 2017 | $-0.63 | $-0.71 | -12.45% |
Aug 1, 2017 | Jun 2017 | $-0.62 | $-0.63 | -2.32% |
May 2, 2017 | Mar 2017 | $-0.68 | $-0.62 | 9.40% |
Mar 7, 2017 | Dec 2016 | $-0.67 | $-0.72 | -6.78% |
Nov 2, 2016 | Sep 2016 | $-0.66 | $-0.67 | -1.30% |
Aug 3, 2016 | Jun 2016 | $-0.74 | $-0.72 | 2.04% |
May 2, 2016 | Mar 2016 | $-0.65 | $-0.72 | -10.21% |
Mar 1, 2016 | Dec 2015 | $-0.73 | $-0.64 | 11.81% |
Nov 3, 2015 | Sep 2015 | $-0.66 | $-0.56 | 15.15% |
Aug 5, 2015 | Jun 2015 | $-0.70 | $-0.59 | 15.71% |
May 7, 2015 | Mar 2015 | $-0.59 | $-0.59 | - |
Mar 2, 2015 | Dec 2014 | $-0.46 | $-0.59 | -28.26% |
Nov 11, 2014 | Sep 2014 | $-0.40 | $-0.44 | -10.00% |
Aug 6, 2014 | Jun 2014 | $-0.34 | $-0.49 | -44.12% |
May 12, 2014 | Mar 2014 | $-0.35 | $-0.28 | 20.00% |
Mar 18, 2014 | Dec 2013 | $-0.25 | $-0.45 | -80.00% |
Dec 5, 2013 | Sep 2013 | - | $-0.47 | - |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Feb 24, 2022 | Dec 2021 | $-2.79 | $-1.02 | - |
Feb 26, 2021 | Dec 2020 | $-2.98 | $-3.11 | - |
Feb 20, 2020 | Dec 2019 | $-3.18 | $-3.40 | - |
Feb 25, 2019 | Dec 2018 | $-4.59 | $-4.62 | - |
Feb 28, 2018 | Dec 2017 | $-3.25 | $-3.34 | - |
Mar 7, 2017 | Dec 2016 | - | $-2.83 | - |
Mar 1, 2016 | Dec 2015 | - | $-2.38 | - |
Mar 2, 2015 | Dec 2014 | - | $-1.80 | - |
Mar 18, 2014 | Dec 2013 | - | $-0.92 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Aug 2, 2022 | Jun 2022 | $32.62M | - | - |
May 5, 2022 | Mar 2022 | $29.90M | $29.84M | 1.00% |
Feb 24, 2022 | Dec 2021 | $31.45M | $114.67M | 3.65% |
Nov 4, 2021 | Sep 2021 | $28.89M | $29.31M | 1.01% |
Aug 4, 2021 | Jun 2021 | $27.18M | $27.18M | 1.00% |
May 5, 2021 | Mar 2021 | $22.97M | $22.97M | 1.00% |
Feb 26, 2021 | Dec 2020 | $24.68M | $24.68M | 1.00% |
Nov 6, 2020 | Sep 2020 | $19.71M | $20.08M | 1.02% |
Aug 7, 2020 | Jun 2020 | $17.45M | $18.03M | 1.03% |
May 6, 2020 | Mar 2020 | $20.06M | $20.34M | 1.01% |
Feb 20, 2020 | Dec 2019 | $19.46M | $24.66M | 1.27% |
Nov 6, 2019 | Sep 2019 | $17.74M | $18.54M | 1.05% |
Aug 7, 2019 | Jun 2019 | $15.87M | $15.84M | 1.00% |
May 7, 2019 | Mar 2019 | $13.63M | $10.85M | 0.80% |
Feb 25, 2019 | Dec 2018 | $12.94M | $14.46M | 1.12% |
Nov 6, 2018 | Sep 2018 | $5.88M | $7.30M | 1.24% |
Aug 8, 2018 | Jun 2018 | $520.00K | $2.42M | 4.66% |
May 8, 2018 | Mar 2018 | $0.00 | $0.00 | - |
Feb 28, 2018 | Dec 2017 | $0.00 | $0.00 | - |
Nov 8, 2017 | Sep 2017 | $0.00 | $0.00 | - |
Aug 1, 2017 | Jun 2017 | $0.00 | $0.00 | - |
May 2, 2017 | Mar 2017 | - | $0.00 | - |
Mar 7, 2017 | Dec 2016 | - | $0.00 | - |
Nov 2, 2016 | Sep 2016 | - | $0.00 | - |
Aug 3, 2016 | Jun 2016 | - | $0.00 | - |
May 2, 2016 | Mar 2016 | - | $0.00 | - |
Mar 1, 2016 | Dec 2015 | - | $0.00 | - |
Nov 3, 2015 | Sep 2015 | - | $0.00 | - |
Aug 5, 2015 | Jun 2015 | - | $0.00 | - |
May 7, 2015 | Mar 2015 | - | $0.00 | - |
Mar 2, 2015 | Dec 2014 | - | $0.00 | - |
Nov 11, 2014 | Sep 2014 | - | $0.00 | - |
Aug 6, 2014 | Jun 2014 | - | $0.00 | - |
May 12, 2014 | Mar 2014 | - | $0.00 | - |
Mar 18, 2014 | Dec 2013 | - | $0.00 | - |
Dec 5, 2013 | Sep 2013 | - | $0.00 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Feb 24, 2022 | Dec 2021 | $111.08M | $194.13M | 74.77% |
Feb 26, 2021 | Dec 2020 | $83.14M | $83.14M | 0.00% |
Feb 20, 2020 | Dec 2019 | $64.73M | $69.89M | 7.97% |
Feb 25, 2019 | Dec 2018 | $22.69M | $24.18M | 6.57% |
Feb 28, 2018 | Dec 2017 | $0.00 | $0.00 | - |
Mar 7, 2017 | Dec 2016 | - | $0.00 | - |
Mar 1, 2016 | Dec 2015 | - | $0.00 | - |
Mar 2, 2015 | Dec 2014 | - | $0.00 | - |
Mar 18, 2014 | Dec 2013 | - | $0.00 | - |
AERI's next earnings date is Tuesday, Aug 2, 2022 for the fiscal quarter ending Jun 30, 2022.
According to 10 analysts, the average EPS estimation for Aerie Pharmaceuticals's next quarterly earnings is $-0.57, with a low EPS estimation of $-0.72, and a high estimation of $-0.44.
Over the last 1 month, EPS estimates have seen 4 upward revisions and 3 downward. The EPS 1 month trend is $-0.62, the last 2 month trend is $-0.62, and the 3 month trend is $-0.66.
Based on 8 analysts, the average revenue estimation is $32.62M, with a low revenue estimation of $30.50M, and a high estimation of $33.80M.
Aerie Pharmaceuticals's previous earnings date was May 5, 2022 for its fiscal quarter ended Mar 31, 2022.
AERI's earnings per share (EPS) was $-0.66, missing the consensus analysts forecast of $-0.65 by -1.54%.
The EPS was lower than the previous fiscal quarter (Dec 2021) by -160.55%, and higher than the same period a year before (Mar 2021) by -8.33%.
Revenues were $29.84M, worse than the forecast of $29.90M by -0.22%, down by -73.98% from the previous quarter , and up by 29.89% from the same period last year.
The company reported a net income of $-35.89M.Free cash flow for the quarter was $60.31M , compared to $-30.86M last quarter and $-30.83M a year before.
AERI ended the quarter with $337.18M in total debt, an increase of 29.36% compared to the previous quarter, and an increase of 46.56% compared to the same quarter a year before.
Aerie Pharmaceuticals's previous annual earnings date was Feb 24, 2022 for its fiscal year ended Dec 31, 2021.
AERI's earnings per share (EPS) was $-1.02, beating the consensus analysts forecast of $-2.79 by -63.44% , and higher than the previous year's EPS (Dec 2020) by -67.25%.
Revenues were $194.13M, better than the forecast of $111.08M by 74.77%, and up by 133.51% from previous year's revenue.
The company reported a net income of $-74.81M.
Aerie Pharmaceuticals reported a free cash flow of $-102.44M for its fiscal year, compared to $-67.79M a year ago.
The company ended the fiscal year with $260.64M in total debt, an increase of 21.06% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.